Actively Recruiting
Phase 2 Study of Tarlatamab for Men With DLL3-Positive Metastatic Prostate Cancer That Has Returned or Not Responded to Treatment
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-06-17
32
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating tarlatamab as a potential treatment for men with Delta-like Protein 3 DLL3-positive metastatic prostate cancer that has spread to other parts of the body and has either returned after previous treatment or not responded to prior therapy. This Phase 2 study aims to assess the effects of tarlatamab on progression-free survival in this specific group of patients. Participants receive an initial lower dose of tarlatamab on the first day of the first treatment cycle, followed by full doses on subsequent days of the first cycle and on days 1 and 15 of following cycles. This treatment schedule continues throughout the study. The investigational drug is given alone without a placebo or comparison group. During the study, participants will be closely monitored through regular assessments including imaging scans, laboratory tests, and clinical evaluations to track cancer progression and response to the drug. Researchers will measure progression-free survival up to 24 weeks as the main outcome, along with overall response rate. The study involves ongoing safety monitoring and requires participants to follow guidelines related to contraception and prior treatments. Total participation duration varies based on individual treatment cycles and response.
CONDITIONS
Brief Title
A Study of Tarlatamab for People With Prostate Cancer
Research Team
K
Karen Autio, MD
M
Michael Morris, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
